Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Similar Posts
Class 4 Medicines Defect Notification: Ipca Laboratories UK Limited, Various Products, EL(25)A/42
Ipca Laboratories UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.
MHRA approves Siiltibcy as a diagnostic aid for Mycobacterium tuberculosis infection, including disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Siiltibcy
Access, new active substance and biosimilar work sharing initiatives
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
Contact the MHRA
How to contact the MHRA for specific services or enquiries.
Device specific vigilance guidance: Inferior vena cava (IVC) filters
Guidance for manufacturers of IVC filters. It outlines specific scenarios that should be considered when determining if an incident is reportable.
MHRA welcomes Professor Jonathan Benger CBE as new CEO of NICE
Professor Benger’s leadership comes at a pivotal time as the MHRA and NICE deepen collaboration